Search Results

First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression

Innovative Medicine

February 8, 2017

Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for Efficacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease

Innovative Medicine

February 2, 2017

Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions

Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation

Innovative Medicine

January 19, 2017

IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy

First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.

Innovative Medicine

January 5, 2017

Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)

Phase 1b/Phase 2 studies planned in multiple myeloma and solid tumors

Innovative Medicine

December 20, 2016

Janssen Submits Two Applications To FDA Seeking Approval Of Simponi Aria® (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine